Outcomes14

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 14 of 14

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Participants With Adverse Drug Reaction	From Week 1 to 52 weeks at maximum	The analysis population for this outcome measure was the baseline analysis population, which comprised of participants who satisfied the criteria of safety analysis population and had received LYRICA Capsules at least once.	Percentage of Participants	NUMBER
SECONDARY	Percentage of Participants With Serious Adverse Drug Reaction	From Week 1 to52 weeks	The analysis population for this outcome measure was the baseline analysis population, which comprised of participants who satisfied the criteria of safety analysis population and had received LYRICA Capsules at least once.	Percentage of Participants	NUMBER
SECONDARY	Percentage of Participants With Adverse Drug Reaction Unexpected From Japanese Package Insert	From Week 1 to 52 weeks	The analysis population for this outcome measure was the baseline analysis population, which comprised of participants who satisfied the criteria of safety analysis population and had received LYRICA Capsules at least once.	Percentage of Participants	NUMBER
SECONDARY	Number of Participants With Adverse Drug Reactions Related to Peripheral Edema or Other Edema-related Events	From Week 1 to 52 weeks	The analysis population for this outcome measure was the baseline analysis population, which comprised of participants who satisfied the criteria of safety analysis population and had received LYRICA Capsules at least once.	Participants	NUMBER
SECONDARY	Number of Participants With Adverse Drug Reactions Related to Dizziness, Somnolence, Loss of Consciousness, Syncope, and Potential for Accidental Injury	From Week 1 to 52 weeks	The analysis population for this outcome measure was the baseline analysis population, which comprised of participants who satisfied the criteria of safety analysis population and had received LYRICA Capsules at least once.	Participants	NUMBER
SECONDARY	Number of Participants With Adverse Drug Reactions Related to Vision-related Events	From Week 1 to 52 weeks	The analysis population for this outcome measure was the baseline analysis population, which comprised of participants who satisfied the criteria of safety analysis population and had received LYRICA Capsules at least once.	Participants	NUMBER
SECONDARY	Change From Baseline in Pain Score at Week 52	Baseline and at Week 52	The analysis population for this outcome measure comprised of participants for whom the evaluation outcome of pain score was available among the baseline analysis population.	Units on a scale	MEAN
SECONDARY	Change From Baseline in Quality of Sleep Score at Week 52	Baseline and at Week 52	The analysis population for this outcome measure comprised of participants for whom the evaluation outcome of quality of sleep score was available among the baseline analysis population.	Units on a scale	MEAN
SECONDARY	Patient's Impression (PGIC) at Week 52	At Week 52	The analysis population for this outcome measure comprised of participants for whom the evaluation outcome of PGIC was available among the baseline analysis population.	Participants	NUMBER
SECONDARY	Physician's Impression (CGIC) at Week 52	At Week 52	The analysis population for this outcome measure comprised of participants for whom the evaluation outcome of CGIC was available among the baseline analysis population.	Participants	NUMBER
SECONDARY	Change From Baseline in Patient Health Questionnaire (PHQ-9) Score at Week 52	Baseline and at Week 52	The analysis population for this outcome measure comprised of participants for whom the evaluation outcome of PHQ-9 was available among the baseline analysis population.	Units on a scale	MEAN
SECONDARY	Change From Baseline in Health Status of EuroQol 5 Dimension (EQ-5D) at 52 Weeks	Baseline and at Week 52	The analysis population for this outcome measure comprised of participants for whom the evaluation outcome of EQ-5D was available among the baseline analysis population.	Units on a scale	MEAN
SECONDARY	Change From Baseline in Fibromyalgia Activity Score (FAS-31) at 52 Weeks	At Week 52	The analysis population for this outcome measure comprised of participants for whom the evaluation outcome of FAS-31 was available among the baseline analysis population.	Units on a scale	MEAN
SECONDARY	Change From Baseline in the Japanese Version of the Revised Fibromyalgia Impact Questionnaire (JFIQR) at 52 Weeks	At Week 52	The analysis population for this outcome measure comprised of participants for whom the evaluation outcome of JFIQR was available among the baseline analysis population.	Units on a scale	MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01773993/outcomes

API reference For AI assistants